When will evantumumab be launched in China?

Amivantamab is a fully human bispecific monoclonal antibody targeting the dual channels of EGFR and MET. It is mainly used to treat patients with a special mutation type in non-small cell lung cancer (NSCLC) - EGFR exon 20 insertion mutation (exon20ins) positive patients. Such mutations are not uncommon in Chinese lung cancer patients, but there was a lack of effective targeted drugs in the past. The emergence of evantumumab has filled this treatment gap. According to an announcement issued by the National Medical Products Administration (NMPA) in early 2025, evantumumab has been officially approved for marketing in China. It is indicated for adult patients with locally advanced or metastatic NSCLC positive for EGFR exon20 insertion mutations that have progressed after platinum-based chemotherapy. This approval marks another big step in the introduction of innovative targeted drugs in China.

Although evantumumab has completed registration and approval in China, due to the short launch time of 2025, hospitals and pharmacy channels are still gradually establishing a supply system, resulting in clinical accessibility still relatively limited. When some patients try to find drugs, they may face practical problems such as insufficient drug supply or lack of coverage by medical insurance. Especially in some non-tertiary hospitals or local medical institutions, patients still cannot easily obtain the drug. Therefore, for patients in urgent need of treatment, they may consider obtaining the overseas version of evantumumab that has been marketed in the United States, Europe or other Asian countries through regular international pharmacies or cross-border medical platforms to ensure the continuity and timeliness of treatment.

Globally, the clinical application of evantumumab has been recognized by multiple regulatory agencies. The United StatesFDA approved its marketing as early as 2021, and the European Medicines Agency (EMA) also approved its authorization in 2022, making it gradually become one of the important options for the treatment of EGFR exon20ins mutated lung cancer worldwide.

Reference materials:https://www.rybrevant.com/